AC Immune is a clinical stage biopharmaceutical company focused on developing medicine for neurodegenerative diseases. Co.'s clinical stage product candidates include: ACI-35.030, which targets pathological Tau and is intended as a disease-modifying treatment for Alzheimer's disease (AD) and other Tauopathies; Semorinemab, which is designed to slow the prion-like propagation of Tau pathology; ACI-24, in which it owns the global rights to ACI-24 and it develops ACI-24 in-house for AD and Down syndrome-related AD; and diagnostic candidates, in which it continues to develop its complementary diagnostic product candidates for Tau, a-syn (with Life Molecular Imaging SA) and TDP-43. We show 7 historical shares outstanding datapoints in our ACIU shares outstanding history coverage, used to compute ACIU market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACIU market cap history over the course of time is important for investors
interested in comparing ACIU's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACIU versus a peer is one thing; comparing
ACIU market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACIU can fluctuate over the course of history.
With this page we aim to empower investors researching ACIU by allowing them to research the ACIU market cap history. |
Free ACIU Email Alerts:
Video: The Importance of Market Cap
